疫苗衍生2型脊髓灰质炎病毒暴发应对方案评估:巴基斯坦卡拉奇随机对照试验
在22周龄2型脊髓灰质炎病毒(PV2)血清阴性儿童中比较四种暴发应对方案,265名儿童数据显示mOPV2免疫原性优于tOPV,OPV联合IPV优于单用OPV,mOPV2排毒率高于tOPV,tOPV联合IPV排毒率低于单用tOPV,支持WHO将mOPV2作为cVDPV2暴发应对首选疫苗的推荐。
要点
- mOPV2血清阳转率76%高于tOPV的48%(p<0.001),mOPV2免疫原性更强。
- OPV联合IPV血清阳转率98%高于单用tOPV的48%(p<0.001),tOPV联合IPV优于单用OPV。
- mOPV2排毒率67%高于tOPV的33%(p<0.001),tOPV联合IPV排毒率20%低于单用tOPV的33%(p=0.046)。
核心结论
- mOPV2是比tOPV更强效的疫苗;在OPV基础上加用IPV改善了免疫应答,加用IPV似乎还缩短了PV2排毒持续时间;与常规IPV相比,mIPV2未提供可测量的免疫应答改善;本研究结果支持WHO关于将mOPV2作为cVDPV2暴发应对首选疫苗的推荐。
研究设计与样本
- 随机对照试验,在巴基斯坦卡拉奇开展,纳入22周龄时PV2血清阴性的儿童,分别接受一剂tOPV、mOPV2、tOPV联合一剂IPV或mOPV2联合单价高效价2型IPV,采集粪便和血液样本检测PV2及抗脊髓灰质炎抗体,共分析265名PV2血清阴性儿童数据。
主要发现
- 第1至4组PV2血清阳转率分别为48%、76%、98%和100%。
- mOPV2免疫原性高于单用tOPV(p<0.001);OPV联合IPV免疫原性高于单用OPV(p<0.001)。
- 第1至4组PV2排毒者比例分别为33%、67%、20%和43%。
- mOPV2排毒比使用tOPV更普遍(p<0.001);tOPV联合IPV的PV2排毒低于单用tOPV(p=0.046)。
临床怎么用
- WHO推荐将mOPV2作为cVDPV2暴发应对的首选疫苗,本研究结果支持该推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outbreaks of circulating vaccine derived polioviruses type 2 (cVDPV2) remain a risk to poliovirus eradication in an era without live poliovirus vaccine containing type 2 in routine immunization. We evaluated existing outbreak response strategies recommended by the World Health Organization (WHO) for control of cVDPV2 outbreaks. METHODS: Seronegative children for poliovirus type 2 (PV2) at 22 weeks of life were assigned to one of four study groups and received respectively (1) one dose of trivalent oral poliovirus vaccine (tOPV); (2) monovalent OPV 2 (mOPV2); (3) tOPV together with a dose of inactivated poliovirus vaccine (IPV); or (4) mOPV2 with monovalent high-potency IPV type 2. Stool and blood samples were collected and assessed for presence of PV2 (stool) and anti-polio antibodies (sera). RESULTS: We analyzed data from 265 children seronegative for PV2. Seroconversion to PV2 was achieved in 48, 76, 98 and 100% in Groups 1-4 respectively. mOPV2 was more immunogenic than tOPV alone (p < 0.001); and OPV in combination with IPV was more immunogenic than OPV alone (p < 0.001). There were 33%, 67%, 20% and 43% PV2 excretors in Groups 1-4 respectively. mOPV2 resulted in more prevalent shedding of PV2 than when tOPV was used (p < 0.001); and tOPV together with IPV resulted in lower excretion of PV2 than tOPV alone (p = 0.046). CONCLUSION: mOPV2 was a more potent vaccine than tOPV. Adding IPV to OPV improved immunological response; adding IPV also seemed to have shortened the duration of PV2 shedding. mIPV2 did not provide measurable improvement of immune response when compared to conventional IPV. WHO recommendation to use mOPV2 as a vaccine of first choice in cVDPV2 outbreak response was supported by our findings. Clinical Trial registry number: NCT02189811.
引用
- Saleem AF, Yousafzai MT, Mach O, et al. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. Vaccine. 2018. PMID: 29477307. doi:10.1016/j.vaccine.2018.02.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。